Cognitive Impairment in Patients with Type 2 Diabetes Mellitus
Keywords:
Diabetes, cognitive impairment, MMSE, FAB - test, cognitive status, diabetic encephalopathy, meantime hydrochloride, cerebrolysinAbstract
The nervous system is one of the main targets for diabetes mellitus. The pathology of the peripheral nervous system in diabetic neuropathies is well studied, which cannot be said about lesions of the central nervous system and, first of all, the brain. The most common manifestation of brain dysfunction in diabetes is cognitive impairment. This article is devoted to the relationship between cognitive impairment and type 2 diabetes.
References
AbbatecolaAM, Rizzo MR, Barbieri M. et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics // Neurology. 2006; V. 67: 235-240.
AlafuzofI., AhoL., HelisalmiS. et al. β -Amyloid deposition in brains of subjects with diabetes // Neuropathol . Appl. Neurobiol . 2009; V.35:60-68.
ArvanitakisZ. et al.Diabetes is related to cerebral infarction but not to AD pathology in older persons // Neurology. 2006; V.67: 1960-1965.
BeeriM. et al.Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology // Neurology. 2008; V.71: 750-757.
BiesselsGJ, StaekenborgS., Brunner E. et al.Risk of dementia in diabetes mellitus: a systematic review // Lancet Neurol. 2006; V.5:64–74.
Craft S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia // Arch. Neurol. 2009. V.66: 300-305.
DCCT/EDIC Study Research Group. Long-Term efectof diabetes and its treatment on cognitive function // New Engl.J.Med . 2007; V.356: 1842-1852.
IrieF., Fitzpatrick AL, Lopez OL Enhanced Risk for Alzheimer Disease in Persons WithType 2 Diabetes and APOE-4 //Arch. Neurol. 2008; V.65: 89-93.
KalariaRN Diabetes, microvascular pathology and Alzheimer disease // Nature Rev. Neurology. 2009; V.5: 305-306.
LuchsingerJA, Tang MX, Stern Y. et al. Diabetes mellitus and risk of dementia in a multiethnic cohort // Am. J. epidemiol . 2001; V.154: 635-641.
MacKnightC., Rockwood K., AwaltE. et al. Diabetes mellitus and the risk of Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging // Dement GeriatrCognDiscord . 2002; V.14:77-83.
MoesslerH. Treatment of Alzheimer's disease: new insight into pharmacology and clinical profile of the neurotrophic compound cerebrolysin// Research and Practice in Alzheimer's disease. Paris, Springer. 2003; 266-275.
MusiccoM., Palmer K., SalamoneG. et al.Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors // J. Neurol. 2009; V.256: 1288-1295.
MijnhoutGS ScheltensP., DiamantM. et al. Diabetic encephalopathy: a concept in need of a defnition// Diabetologia . 2006; V. 49: 1447-1448.
Nelson PT et al. Human cerebral neuropathology of type 2 diabetes mellitus // Biochim .Biophys . Acta . 2008; V.1792: 454-469.
PanissetM., Gauthier S., MoesslerH. et al. Cerebrolysinin Alzheimer's disease: a randomized double-blind placebo-controlled trial with a neurotrophic agent.// J. Neural . Trans., 2002. -V.109. – P.1089-1104.
